通策医疗所属申万行业为：医药生物-医疗服务-医院。所属概念板块包括：辅助生殖、DeepSeek概念、 民营医院、区块链、口腔医疗等。 通策医疗今年以来股价涨12.41%，近5个交易日涨4.15%，近20日涨10.19%，近60日涨6.60%。 资料显示，通策医疗股份有限公司位于杭州市西湖区西溪路双口井巷1号通策医疗大厦，成立日期1995 年8月30日，上市日期1996年10月30日，公司主营业务涉及医疗服务投资及口腔医疗服务。主营业务收 入构成为：医疗服务92.84%，产品销售4.06%，建筑工程2.72%，其他0.38%。 机构持仓方面，截止2025年9月30日，通策医疗十大流通股东中，华宝中证医疗ETF（512170）位居第 三大流通股东，持股888.54万股，相比上期减少158.04万股。南方中证500ETF（510500）位居第五大流 通股东，持股456.41万股，相比上期减少10.67万股。广发聚瑞混合A（270021）位居第六大流通股东， 持股337.66万股，持股数量较上期不变。广发盛兴混合A（011136）位居第七大流通股东，持股321.41 万股，为新进股东。香港中央结算有限公司位居第八大流 ...

该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88。 证券之星消息，截至2026年1月20日收盘，通策医疗(600763)报收于44.3元，下跌1.77%，换手率 2.26%，成交量10.1万手，成交额4.49亿元。 1月20日的资金流向数据方面，主力资金净流出5949.89万元，占总成交额13.24%，游资资金净流入 1962.08万元，占总成交额4.37%，散户资金净流入3987.81万元，占总成交额8.87%。 近5日资金流向一览见 ...

证券之星消息，截至2026年1月19日收盘，通策医疗(600763)报收于45.1元，上涨0.6%，换手率3.42%， 成交量15.31万手，成交额6.94亿元。 1月19日的资金流向数据方面，主力资金净流入3353.37万元，占总成交额4.83%，游资资金净流入 1948.57万元，占总成交额2.81%，散户资金净流出5301.94万元，占总成交额7.64%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.8 ...

1月19日，通策医疗盘中上涨2.01%，截至10:24，报45.73元/股，成交2.74亿元，换手率1.36%，总市值 204.55亿元。 资金流向方面，主力资金净流入826.25万元，特大单买入743.27万元，占比2.71%，卖出492.62万元，占 比1.80%；大单买入5494.17万元，占比20.06%，卖出4918.57万元，占比17.96%。 通策医疗今年以来股价涨13.73%，近5个交易日涨8.01%，近20日涨11.37%，近60日涨8.39%。 分红方面，通策医疗A股上市后累计派现3.92亿元。近三年，累计派现3.40亿元。 机构持仓方面，截止2025年9月30日，通策医疗十大流通股东中，华宝中证医疗ETF（512170）位居第 三大流通股东，持股888.54万股，相比上期减少158.04万股。南方中证500ETF（510500）位居第五大流 通股东，持股456.41万股，相比上期减少10.67万股。广发聚瑞混合A（270021）位居第六大流通股东， 持股337.66万股，持股数量较上期不变。广发盛兴混合A（011136）位居第七大流通股东，持股321.41 万股，为新进股东。香港中央结算 ...

Q&A 截至 2025 年底，通策医疗的医院、牙椅和医生数量分别是多少？ 截至 2025 年底，通策医疗共有 96 个医疗机构网点，其中新增较多的是蒲公 英和娄底片区。牙椅数量约为 3,100 多台，医生人数大约在 1,600 多人。主要 贡献营收和利润的医院仍集中在浙江省内。 浙江省内的收入占整体收入的 90%左右，而杭州市内的收入占比大概为 50%。 浙江省内及杭州市内的收入占比情况如何？ 通策医疗 20260116 摘要 通策医疗 2025 年预计营收保持个位数增长，全年业绩增幅预计在 0% 到 5%之间，四季度为传统淡季，费用摊销较多。 公司设定 2026 年收入增长 30%的目标，重点发展种植和正畸业务，计 划种植牙从 2025 年的 6 万例增至 20 万例，正畸从 2 万例增至 5 万例。 为实现增长目标，公司将推行医院条线改革，优化医生排班，提高接诊 能力和客单价；同时，采用网格化管理进行市场推广，并推出适应市场 需求的新产品。 公司拥有超过 400 人的 C 级以上种植医生团队，完全能够支持 20 万颗 种植牙目标，另有 200 人的正畸医生团队，产能充足。 营销方面，公司通过网格员推广产品 ...

Group 1 - The A-share market opened lower on January 15, with AI application themes retreating and sectors like CRO, commercial aerospace, brain-computer interfaces, and nuclear fusion concepts experiencing significant declines [1] - As of January 13, over 70 billion yuan of public fund capital has flowed into the equity market for 2026, with newly launched rights funds, newly established funds still in the building phase for 2025, and on-site trading open-end index funds being the three main channels [1] - CITIC Securities forecasts that the global interest rate cut cycle will enter its second half in 2026, characterized by "internal and external easing resonance" and a shift from "extraordinary to normal" macro liquidity [1] Group 2 - The A500 ETF (512050) provides investors with a convenient way to invest in core A-share assets, benefiting from valuation increases, with advantages such as a low fee rate of 0.2%, good liquidity with an average daily trading volume exceeding 5 billion yuan, and a large scale of over 40 billion yuan [2] - The A500 ETF tracks the CSI A500 Index, employing a dual strategy of industry balanced allocation and leading stock selection, covering all 35 sub-industries and integrating value and growth attributes [2] - Investors are encouraged to consider related products such as the A500 ETF (512050) and the A500 Enhanced ETF (512370) [2]

Group 1 - The Shanghai Composite Index is at 4107.01 points, above the six-month moving average, with a decline of 0.46% [1] - The total trading volume of A-shares today is 1,429.956 billion yuan [1] - A total of 98 A-shares have surpassed the six-month moving average, with notable stocks including Xinweiling, Shenyu Co., and Wenkex Co., showing significant deviation rates of 7.90%, 7.78%, and 7.77% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the six-month moving average are: - Xinweiling (12.46% increase, 10.41% turnover rate, latest price 29.97 yuan, deviation rate 7.90%) [1] - Shenyu Co. (8.73% increase, 12.74% turnover rate, latest price 41.98 yuan, deviation rate 7.78%) [1] - Wenkex Co. (10.09% increase, 3.41% turnover rate, latest price 4.80 yuan, deviation rate 7.77%) [1] Group 3 - Other notable stocks with significant increases and their respective deviation rates include: - Tongce Medical (8.32% increase, 7.01% turnover rate, latest price 47.01 yuan, deviation rate 7.22%) [1] - Dibei Electric (10.01% increase, 6.78% turnover rate, latest price 20.88 yuan, deviation rate 7.10%) [1] - Guangming Real Estate (10.09% increase, 1.66% turnover rate, latest price 3.82 yuan, deviation rate 6.06%) [1]

通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 证券之星消息，截至2026年1月13日收盘，通策医疗(600763)报收于42.48元，上涨0.33%，换手率 3.4%，成交量15.21万手，成交额6.53亿元。 1月13日的资金流向数据方面，主力资金净流出1238.96万元，占总成交额1.9%，游资资金净流入 1690.08万元，占总成交额2.59%，散户资金净流出451.12万元，占总成交额0.69%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

证券日报网讯 1月12日，通策医疗在互动平台回答投资者提问时表示，截至2026年1月10日公司股东总 数为9万多户。为确保所有投资者能公平地获取信息，相关股东人数信息后续请以公司正式披露的定期 报告为准。 （文章来源：证券日报） ...